EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

D Ross Camidge iD, Fabrice Barlesi, Jonathan W Goldman iD, Daniel Morgensztern iD, Rebecca Heist iD, Everett Vokes iD, Alex Spira iD, Eric Angevin iD, Wu-Chou Su, David S Hong iD, John H Strickler iD, Monica Motwani und 6 weitere

Journal of Clinical Oncology · 10.02.2023 · 41 (5) · 1105-1115

DOI: 10.1200/jco.22.00739 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2023. Verfasst von D Ross Camidge und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Cancer Center, Aurora, CO. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Overexpression of c-Met protein and epidermal growth factor receptor ( EGFR) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy. Herein, we report the results of a phase Ib study (ClinicalTrials.gov identifier: NCT02099058 ) evaluating Teliso-V plus erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met–positive (+) NSCLC. PATIENTS AND METHODS This study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 years) with c-Met+ NSCLC. Later enrollment required presence of an EGFR-activating mutation ( EGFR-M +) and progression on a prior EGFR TKI. End points included safety, pharmacokinetics, objective response rate (ORR), and progression-free survival (PFS). The efficacy-evaluable population consisted of c-Met+ patients (confirmed histology [H]-score ≥ 150) who had at least one postbaseline scan; c-Met+ patients with H-scores ≥ 225 were classified as c-Met high. RESULTS As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached). ORR for EGFR-M + patients (n = 28) was 32.1%. Of EGFR-M + patients, those who were c-Met high (n = 15) had an ORR of 52.6%. Median PFS was 6.8 months for non-T790M+ and for those whose T790M status was unknown, versus 3.7 months for T790M+. CONCLUSION Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultHumansAdolescentErlotinib HydrochlorideMutationErbB ReceptorsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal

Substanzen

Erlotinib HydrochlorideErbB ReceptorsProtein Kinase Inhibitorstelisotuzumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • University of Colorado Cancer Center, Aurora, CO.
  • Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Inserm U911 CRO2, Marseille, France.
  • Medical Oncology Department, Gustave Roussy, Villejuif, France.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Washington University School of Medicine, St Louis, MO.
  • Massachusetts General Hospital Cancer Center, Boston, MA.

ORCID-Profile: D Ross Camidge, Jonathan W Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Alex Spira, Eric Angevin, David S Hong, John H Strickler, Apurvasena Parikh, Karen Kelly

Förderung

  • NCI NIH HHS

Zitieren

APA

Camidge, D. R., Barlesi, F., Goldman, J. W., Morgensztern, D., Heist, R., Vokes, E., Spira, A., Angevin, E., Su, W. C., Hong, D. S., Strickler, J. H., Motwani, M., Dunbar, M., Parikh, A., Noon, E., Blot, V., Wu, J., & Kelly, K. (2023). Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 41(5), 1105-1115. https://doi.org/10.1200/jco.22.00739

Vancouver

Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2023;41(5):1105-1115. doi:10.1200/jco.22.00739

BibTeX
@article{Camidge2023,
  author = {Camidge, D Ross and Barlesi, Fabrice and Goldman, Jonathan W and Morgensztern, Daniel and Heist, Rebecca and Vokes, Everett and Spira, Alex and Angevin, Eric and Su, Wu-Chou and Hong, David S and Strickler, John H and Motwani, Monica and Dunbar, Martin and Parikh, Apurvasena and Noon, Elysa and Blot, Vincent and Wu, Jun and Kelly, Karen},
  title = {Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {5},
  pages = {1105--1115},
  doi = {10.1200/jco.22.00739}
}
Kostenlos starten →